Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 27;58(12):1733.
doi: 10.3390/medicina58121733.

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

Qinglu Fan  1 , Zhihao Nie  1 , Songping Xie  1
Affiliations
Review

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

Qinglu Fan et al. Medicina (Kaunas). .

Abstract

Since the outbreak of the novel coronavirus disease 2019 (COVID-19) in 2019, many countries have successively developed a variety of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, with the continuous spread of SARS-CoV-2, it has evolved several variants; as a result, prevention and control of the pandemic of SARS-CoV-2 has become more important. Among these variants, the Omicron variant has higher transmissibility and immune escape ability and is the main variant causing a large number of COVID-19 breakthrough infection, thus, presenting new challenges to pandemic prevention and control. Hence, we review the biological characteristics of the Omicron variant and discuss the current status and possible mechanism of breakthrough infection caused by the Omicron variant in order to provide insights into the prevention and control of the pandemic of SARS-CoV-2.

Keywords: COVID-19; Omicron; SARS-CoV-2; breakthrough infection; variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. WHO WHO Coronavirus (COVID-19) Dashboard. [(accessed on 24 October 2022)]; Available online: https://covid19.who.int/
    1. Castro G.M., Sicilia P., Bolzon M.L., Lopez L., Barbas M.G., Pisano M.B., Re V.E. Tracking SARS-CoV-2 Variants Using a Rapid Typification Strategy: A Key Tool for Early Detection and Spread Investigation of Omicron in Argentina. Front. Med. (Lausanne) 2022;9:851–861. doi: 10.3389/fmed.2022.851861. - DOI - PMC - PubMed
    1. Noori M., Nejadghaderi S.A., Rezaei N. “Original antigenic sin”: A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants. Infect. Control Hosp. Epidemiol. 2021;43:1091–1092. doi: 10.1017/ice.2021.199. - DOI - PMC - PubMed
    1. Forchette L., Sebastian W., Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Curr. Med. Sci. 2021;41:1037–1051. doi: 10.1007/s11596-021-2395-1. - DOI - PMC - PubMed
    1. Fan Y., Li X., Zhang L., Wan S., Zhang L., Zhou F. SARS-CoV-2 Omicron variant: Recent progress and future perspectives. Signal Transduct. Target. Ther. 2022;7:141. doi: 10.1038/s41392-022-00997-x. - DOI - PMC - PubMed

Supplementary concepts